Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71(3):209–249. doi:10.3322/caac.21660
   Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA. 2019;69(5):363–385. doi:10.3322/caac.21565
   Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–127. doi:10.1111/joim.12019
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299–309. doi:10.1016/j.ccr.2005.09.005
   PubMed Web of Science ®Google Scholar
• Qiang H, Chang Q, Xu J, et al. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2020;146(3):631–645. doi:10.1007/s00432-020-03129-6
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Syed YY. Anlotinib: first Global Approval. Drugs. 2018;78(10):1057–1062. doi:10.1007/s40265-018-0939-x
   PubMed Web of Science ®Google Scholar
• Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018;654:77–86. doi:10.1016/j.gene.2018.02.026
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Zhao Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised Phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654–661. doi:10.1038/bjc.2017.478
   PubMed Web of Science ®Google Scholar
• Liu S, Qin T, Liu Z, et al. anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309. doi:10.1038/s41419-020-2511-3
   PubMed Web of Science ®Google Scholar
• Yang Y, Li L, Jiang Z, Wang B, Pan Z. Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother. 2020;69(12):2523–2532. doi:10.1007/s00262-020-02641-5
   PubMed Web of Science ®Google Scholar
• Su Y, Luo B, Lu Y, et al. Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma. Clin Cancer Res. 2021;2021:1.
   Google Scholar
• Liu Y, Long L, Liu J, Zhu L, Luo F. Case report: anlotinib reverses nivolumab resistance in advanced primary pulmonary lymphoepithelioma-like carcinoma with FGFR3 gene amplification. Front Oncol. 2021;11:749682. doi:10.3389/fonc.2021.749682
   PubMed Web of Science ®Google Scholar
• Luo Y, Wei J, Zhang J, Zeng L, Zeng Z, Liu A. Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib. Lung Cancer. 2021;155:170–174. doi:10.1016/j.lungcan.2021.03.019
   PubMed Web of Science ®Google Scholar
• Su H, Yu C, Ma X, Song Q. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review. Invest New Drugs. 2021;39(5):1411–1418. doi:10.1007/s10637-021-01105-6
   PubMed Web of Science ®Google Scholar
• Jin C, Yang B. Dramatic response of pulmonary sarcomatoid carcinoma to nivolumab combined with anlotinib: a case report. Case Rep Oncol. 2020;13(2):601–605. doi:10.1159/000507568
   PubMed Web of Science ®Google Scholar
• Wang P, Fang X, Yin T, Tian H, Yu J, Teng F. Efficacy and safety of anti-PD-1 plus anlotinib in patients with advanced non-small-cell lung cancer after previous systemic treatment failure-A retrospective study. Front Oncol. 2021;11:628124. doi:10.3389/fonc.2021.628124
   PubMed Web of Science ®Google Scholar
• Wang Y, Shi X, Qi Q, Ye B, Zou Z. Safety of anlotinib capsules combined with PD-1 inhibitor camrelizumab in the third-line treatment of advanced non-small-cell lung cancer and their effect on serum tumor markers. J Healthc Eng. 2021;2021:2338800. doi:10.1155/2021/2338800
   PubMed Web of Science ®Google Scholar
• Xiong Q, Qin B, Xin L, et al. Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer. Front Oncol. 2021;11:659380. doi:10.3389/fonc.2021.659380
   PubMed Web of Science ®Google Scholar
• Yuan M, Zhu Z, Mao W, et al. Anlotinib combined with anti-PD-1 antibodies therapy in patients with advanced refractory solid tumors: a single-center, observational, prospective study. Front Oncol. 2021;11:683502. doi:10.3389/fonc.2021.683502
   PubMed Web of Science ®Google Scholar
• Zhang C, Kong FW, Wu WB, et al. First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: a case report and review of the literature. Medicine. 2020;99(36):e22128. doi:10.1097/MD.0000000000022128
   PubMed Web of Science ®Google Scholar
• Manegold C, Dingemans AC, Gray JE, et al. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J Thorac Oncol. 2017;12(2):194–207. doi:10.1016/j.jtho.2016.10.003
   PubMed Web of Science ®Google Scholar
• Tabchi S, Blais N. Antiangiogenesis for advanced non-small-cell lung cancer in the era of immunotherapy and personalized medicine. Front Oncol. 2017;7:52. doi:10.3389/fonc.2017.00052
   PubMed Web of Science ®Google Scholar
• Attili I, Passaro A, Pavan A, Conte P, De Marinis F, Bonanno L. Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): does biological rationale meet clinical needs? Crit Rev Oncol Hematol. 2017;119:30–39. doi:10.1016/j.critrevonc.2017.09.007
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. doi:10.1186/s12943-019-0974-6
   PubMed Web of Science ®Google Scholar
• Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301. doi:10.1056/NEJMoa1716948
   PubMed Web of Science ®Google Scholar
• Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401. doi:10.1016/S2213-2600(19)30084-0
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase iii study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33(19):2197–2204. doi:10.1200/JCO.2014.59.4424
   PubMed Web of Science ®Google Scholar
• Lu H, Jiang Z. Advances in antiangiogenic treatment of small-cell lung cancer. Onco Targets Ther. 2017;10:353–359. doi:10.2147/OTT.S119714
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244. doi:10.1016/S1470-2045(14)70381-X
   PubMed Web of Science ®Google Scholar
• Rahma OE, Hodi FS. The intersection between tumor angiogenesis and immune suppression. Clin Cancer Res. 2019;25(18):5449–5457. doi:10.1158/1078-0432.CCR-18-1543
   PubMed Web of Science ®Google Scholar
• Wang HY, Chu JF, Zhao Y, et al. A trial of the safety and efficacy of chemotherapy plus anlotinib vs chemotherapy alone as second- or third-line salvage treatment for advanced non-small cell lung cancer. Cancer Manag Res. 2020;12:3827–3834. doi:10.2147/CMAR.S249678
   PubMed Web of Science ®Google Scholar
• Lian Z, Du W, Zhang Y, et al. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation. Thorac Cancer. 2020;11(7):1934–1943. doi:10.1111/1759-7714.13485
   PubMed Web of Science ®Google Scholar
• Lei T, Xu T, Zhang N, et al. Anlotinib combined with osimertinib reverses acquired osimertinib resistance in NSCLC by targeting the c-MET/MYC/AXL axis. Pharm Res. 2023;188:106668. doi:10.1016/j.phrs.2023.106668
   Google Scholar
• Si X, Zhang L, Wang H, et al. Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: experiences in ALTER-0303. Thorac Cancer. 2019;10(3):551–556. doi:10.1111/1759-7714.12977
   PubMed Web of Science ®Google Scholar
• Zhang K, Ma X, Gao H, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study. Cancer Manag Res. 2020;12:3409–3417. doi:10.2147/CMAR.S246000
   PubMed Web of Science ®Google Scholar
• Lv B, Chen J, Liu XL. Anlotinib-induced hypertension: current concepts and future prospects. Curr Pharm Des. 2021;28:216–224.
   Web of Science ®Google Scholar
• Wang L, He Z, Yang S, et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. Transl Lung Cancer Res. 2019;8(5):575–583. doi:10.21037/tlcr.2019.09.21
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009;15(3):167–170. doi:10.1016/j.ccr.2009.02.007
   PubMed Web of Science ®Google Scholar
• Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26(5):605–622. doi:10.1016/j.ccell.2014.10.006
   PubMed Web of Science ®Google Scholar
• Li S, Cao C, Huang Z, et al. SOD2 confers anlotinib resistance via regulation of mitochondrial damage in OSCC. Oral Dis. 2022. doi:10.1111/odi.14404
   Web of Science ®Google Scholar
• Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol. 2012;30(32):4026–4034. doi:10.1200/JCO.2012.41.9242
   PubMed Web of Science ®Google Scholar
• Huijbers EJ, van Beijnum JR, Thijssen VL, Sabrkhany S, Nowak-Sliwinska P, Griffioen AW. Role of the tumor stroma in resistance to anti-angiogenic therapy. Drug Resist Updat. 2016;25:26–37. doi:10.1016/j.drup.2016.02.002
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008;8(8):592–603. doi:10.1038/nrc2442
   PubMed Web of Science ®Google Scholar